Subtype
Lung Carcinoma
CI-CAN-00001086Explore in graph →
2,130 active trials51 approved drugs598 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001086Explore in graph →
Clinical trials
7,792 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,179)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03156114 | This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment. | completed | Phase 1 | 172 | Boehringer IngelheimINDUSTRY | 5 | Jan 26, 2026 | clinicaltrials |
| NCT07348211 | First in Human Study of SIM0610 in Solid Tumors(SIM0610-101) | recruiting | Phase 1 | 260 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 |
| Jan 23, 2026 |
| clinicaltrials |
| NCT07362940 | A Phase Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With Dositinib | recruiting | Phase 1 / Phase 2 | 110 | Henan Genuine Biotech Co., Ltd.INDUSTRY | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07358806 | Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 51 | Oscotec Inc.INDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT07358884 | First in Human Study of QLS5316 in Solid Tumors | not yet recruiting | Phase 1 | 300 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Jan 22, 2026 | clinicaltrials |
| NCT02408861 | Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | terminated | Phase 1 | 79 | National Cancer Institute (NCI)NIH | 2 | Jan 21, 2026 | clinicaltrials |
| NCT03891953 | Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. | active not recruiting | Phase 1 | 98 | Novartis PharmaceuticalsINDUSTRY | 6 | Jan 21, 2026 | clinicaltrials |
| NCT06612840 | A Study of GNC-077 in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer and Other Solid Tumors | recruiting | Phase 1 | 20 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 21, 2026 | clinicaltrials |
| NCT03003468 | Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017 | completed | Phase 1 / Phase 2 | 35 | Lawrence Feldman, MDOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT03467360 | Phase I Trial of CArbonic Anhydrase Inhibition in Combination With Radiochemotherapy or Radioimmunotherapy in Small Cell Lung Carcinoma(ICAR) | recruiting | Phase 1 | 27 | Centre Antoine LacassagneOTHER | 2 | Jan 20, 2026 | clinicaltrials |
| NCT03575793 | A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 39 | Salma SabbourOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT04743505 | Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) | active not recruiting | Phase 1 / Phase 2 | 27 | Washington University School of MedicineOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT05302817 | Functional Lung Avoidance Radiation Therapy Using Hyperpolarized Xenon-129 MRI | terminated | Phase 1 | 9 | Xemed LLCINDUSTRY | 1 | Jan 20, 2026 | clinicaltrials |
| NCT07351565 | Chemotherapy Plus Pitavastatin Guided by Patient-Derived Tumor-like Cell Clusters in Refractory Non-Small Cell Lung Cancer(CPPGPTCLC) | not yet recruiting | Phase 1 | 22 | Chang ChenOTHER | 0 | Jan 20, 2026 | clinicaltrials |
| NCT06879717 | A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients(PULMO-01) | active not recruiting | Phase 1 / Phase 2 | 45 | iOncturaINDUSTRY | 3 | Jan 16, 2026 | clinicaltrials |
| NCT07339839 | Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLC | not yet recruiting | Phase 1 / Phase 2 | 42 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Jan 14, 2026 | clinicaltrials |
| NCT00596648 | A Study of XL184 (Cabozantinib) With or Without Erlotinib in Subjects With Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 1 / Phase 2 | 92 | ExelixisINDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT03780725 | This Study Tests How BI 754111 is Distributed in Patients With Advanced Non-small Cell Lung Cancer or Patients With Head and Neck Cancer Who Are Treated With BI 754091 | terminated | Phase 1 | 8 | Boehringer IngelheimINDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT05002270 | JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation | completed | Phase 1 / Phase 2 | 29 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT07219576 | Retifanlimab and Ruxolitinib In Solid Malignancies(PRISM) | recruiting | Phase 1 / Phase 2 | 40 | University of California, San DiegoOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT04260802 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers | terminated | Phase 1 / Phase 2 | 73 | Ocellaris Pharma, Inc.INDUSTRY | 1 | Jan 12, 2026 | clinicaltrials |
| NCT05074810 | Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients(RAMP203) | active not recruiting | Phase 1 / Phase 2 | 153 | Verastem, Inc.INDUSTRY | 6 | Jan 12, 2026 | clinicaltrials |
| NCT04585815 | Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study) | terminated | Phase 1 / Phase 2 | 34 | PfizerINDUSTRY | 4 | Jan 9, 2026 | clinicaltrials |
| NCT04686682 | A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors | recruiting | Phase 1 / Phase 2 | 152 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 9, 2026 | clinicaltrials |
| NCT05194072 | A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors | terminated | Phase 1 | 250 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 5 | Jan 9, 2026 | clinicaltrials |
| NCT05490472 | JAB-2485 Activity in Adult Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 102 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 2 | Jan 9, 2026 | clinicaltrials |
| NCT06999187 | A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas | recruiting | Phase 1 | 96 | Dren BioINDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT05544929 | A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | active not recruiting | Phase 1 | 126 | Novartis PharmaceuticalsINDUSTRY | 12 | Jan 6, 2026 | clinicaltrials |
| NCT07318636 | NK-cell Therapy Combined With PD-1 Antibody and Platinum-Based Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC | not yet recruiting | Phase 1 | 10 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT05676749 | C-TIL051 in Non-Small Cell Lung Cancer | terminated | Phase 1 | 1 | AbelZeta Inc.INDUSTRY | 1 | Jan 5, 2026 | clinicaltrials |
| NCT05978284 | Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma | recruiting | Phase 1 / Phase 2 | 54 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Jan 5, 2026 | clinicaltrials |
| NCT06903377 | Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 50 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Jan 5, 2026 | clinicaltrials |
| NCT07038096 | ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma | recruiting | Phase 1 / Phase 2 | 350 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Jan 5, 2026 | clinicaltrials |
| NCT04045496 | A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors | completed | Phase 1 | 40 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Dec 29, 2025 | clinicaltrials |
| NCT03810807 | Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer | completed | Phase 1 | 22 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT06512051 | A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 248 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 23, 2025 | clinicaltrials |
| NCT02638090 | Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC) | active not recruiting | Phase 1 / Phase 2 | 120 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT04550104 | A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC(CONCORDE) | recruiting | Phase 1 | 200 | University of LeedsOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT07275073 | JMT106 Injection in the Treatment of Advanced Solid Tumors | recruiting | Phase 1 | 200 | Shanghai JMT-Bio Inc.INDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
| NCT05856981 | Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors | recruiting | Phase 1 | 130 | Sairopa B.V.INDUSTRY | 3 | Dec 17, 2025 | clinicaltrials |
| NCT02621398 | Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer | completed | Phase 1 | 23 | Rutgers, The State University of New JerseyOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT05313009 | Tarlox and Sotorasib in Patients With KRAS G12C Mutations | terminated | Phase 1 / Phase 2 | 5 | Medical University of South CarolinaOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT05652868 | Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer | terminated | Phase 1 | 227 | Mythic TherapeuticsINDUSTRY | 7 | Dec 16, 2025 | clinicaltrials |
| NCT07285148 | A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer | not yet recruiting | Phase 1 / Phase 2 | 253 | Beijing Pearl Biotechnology Limited Liability CompanyINDUSTRY | 1 | Dec 16, 2025 | clinicaltrials |
| NCT06549816 | A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors | completed | Phase 1 | 6 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 1 | Dec 15, 2025 | clinicaltrials |
| NCT03556228 | VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma | recruiting | Phase 1 / Phase 2 | 242 | VM Oncology, LLCINDUSTRY | 2 | Dec 11, 2025 | clinicaltrials |
| NCT06943521 | A Study of MT-4561 in Patients With Various Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 27 | Tanabe Pharma America, Inc.INDUSTRY | 2 | Dec 11, 2025 | clinicaltrials |
| NCT02592577 | MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC | completed | Phase 1 | 28 | AdaptimmuneINDUSTRY | 4 | Dec 9, 2025 | clinicaltrials |
| NCT07271446 | An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer | completed | Phase 1 | 8 | Precision Biotech Taiwan Corp.INDUSTRY | 1 | Dec 9, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Jan 26, 2026source: clinicaltrials